RAPT — Rapt Therapeutics Share News
0.000.00%
Last trade - 00:00Rapt Therapeutics Inc Reports Results For The Quarter Ended June 30: Earnings Summary
RAPT Therapeutics Q2 net loss narrows to $17.6 mln, R&D expenses drop
Rapt Therapeutics Inc Expected To Post A Loss Of 64 Cents A Share: Earnings Preview
U.S. RESEARCH ROUNDUP-Penumbra, UnitedHealth, Visa
Brief: RAPT Therapeutics Announces Effective Date For 1-For-8 Reverse Stock Split
Rapt Therapeutics Inc Reports Results For The Quarter Ended March 31: Earnings Summary
Rapt Therapeutics Inc Expected To Post A Loss Of 13 Cents A Share: Earnings Preview
Rapt Therapeutics Inc Reports Results For The Quarter Ended December 31: Earnings Summary
Brief: Rapt Therapeutics Q4 Net Income USD -53.249 Million
Rapt Therapeutics Inc Expected To Post A Loss Of 37 Cents A Share: Earnings Preview
Brief: Rapt Therapeutics Names Lori Lyons-Williams Chair Of The Board
U.S. RESEARCH ROUNDUP-Apple, EverQuote, UnitedHealth
H.C. Wainwright upgrades Rapt Therapeutics to 'buy' after allergy drug license deal
U.S. STOCKS ON THE MOVE-Walmart, Fiserv, Rumble
U.S. STOCKS ON THE MOVE-Nordstrom, Optical Cable, Lexicon
U.S. STOCKS ON THE MOVE-Eli Lilly, Playa Hotels, Rumble
Rapt Therapeutics rises 60% on license deal for allergy drug
Rapt Therapeutics Inc Reports Results For The Quarter Ended September 30: Earnings Summary
Brief: Rapt Therapeutics Q3 Net Income USD -18.432 Million